<DOC>
	<DOC>NCT01056835</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of Prostaglandin I2 analogue use on the development of chronic allograft nephropathy and changes in allograft function in prevalent renal transplant recipients</brief_summary>
	<brief_title>Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<criteria>prevalent renal transplant recipients 2 years after transplantation no history of acute rejection stable renal function history of biopsyproven chronic allograft nephropathy history of biopsyproven CNI nephrotoxicity history of biopsyproven or clinical acute rejection unstable trough level of CNI or extremely low level of CNI bleeding tendency(+) pregnancy or pregnantwilling anticoagulation(+) antiplatelet agent (+) significant comorbidity(+): Acute coronary syndrome, pneumonia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>